Insider · CIK 0002082076
Jeffrey Sprau
Files at LGN (Legence Corp.). First filing -, latest -.
Jeffrey Sprau files SEC Form 4 as CEO and director at LGN (Legence Corp.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jeffrey Sprau has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | LGN Legence Corp. | FTax withholding Class A Common Stock | -9,792 | $53.03 | $519k | 86,875 | 26 d ago |
| Mar 16, 2026 | LGN Legence Corp. | AGrant or award Class A Common Stock | +34,167 | $0.00 | $0 | 96,667 | Mar 18, 2026 |
| Mar 16, 2026 | LGN Legence Corp. | AGrant or award Employee Stock Optionsderivative | +63,177 | $0.00 | $0 | 63,177 | Mar 18, 2026 |
| Sep 15, 2025 | LGN Legence Corp. | AGrant or award Class A Common Stock | +62,500 | $0.00 | $0 | 62,500 | Sep 15, 2025 |
Questions about Jeffrey Sprau
Answered from the filings on this page, as of the latest one.
Is Jeffrey Sprau buying or selling?
Jeffrey Sprau has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jeffrey Sprau's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey Sprau has 0.
Where does Jeffrey Sprau file Form 4?
Jeffrey Sprau has filed Form 4 at LGN (Legence Corp.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.